Anavex Life Sciences Corp (NASDAQ:AVXL) saw unusually-strong trading volume on Wednesday . Approximately 2,837,900 shares changed hands during mid-day trading, an increase of 622% from the previous session’s volume of 393,254 shares.The stock last traded at $3.03 and had previously closed at $2.36.
Several brokerages recently commented on AVXL. Zacks Investment Research lowered shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. ValuEngine lowered shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Anavex Life Sciences has a consensus rating of “Buy” and an average price target of $9.20.
The stock has a 50-day simple moving average of $2.58 and a 200-day simple moving average of $2.88. The stock has a market cap of $156.90 million, a PE ratio of -6.79 and a beta of 2.17.
About Anavex Life Sciences (NASDAQ:AVXL)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.